Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,878
  • Shares Outstanding, K 14,751
  • Annual Sales, $ 420 K
  • Annual Income, $ -28,450 K
  • EBIT $ -38 M
  • EBITDA $ -38 M
  • 60-Month Beta 1.37
  • Price/Sales 83.15
  • Price/Cash Flow N/A
  • Price/Book 0.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.32
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -55.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.34 +6.84%
on 12/12/24
3.12 -19.87%
on 11/22/24
-0.32 (-11.35%)
since 11/20/24
3-Month
1.79 +39.66%
on 09/30/24
3.43 -27.11%
on 11/06/24
+0.51 (+25.63%)
since 09/20/24
52-Week
1.57 +59.24%
on 06/27/24
3.43 -27.11%
on 11/06/24
-0.10 (-3.85%)
since 12/20/23

Most Recent Stories

More News
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE : 2.50 (+4.60%)
VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis

VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development

VYNE : 2.50 (+4.60%)
Pre-Market Brief: Stocks Mostly Lower As Hawkish Fed Remarks Weigh On Sentiment, Powell Speech In Focus

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices ended the regular session mixed following hawkish remarks from two U.S. Federal Reserve officials,...

ESH23 : 3,957.05s (-0.09%)
AAPL : 254.49 (+1.88%)
GOOGL : 191.41 (+1.54%)
MSFT : 436.60 (-0.10%)
NVDA : 134.70 (+3.08%)
OSH : 39.00 (+0.08%)
VYNE : 2.50 (+4.60%)
FRO : 13.38 (+0.30%)
BLI : 1.2000 (-5.88%)
WWW : 23.06 (+2.72%)
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.50 (+4.60%)
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform

Webinar on Tuesday, May 17, 2022 at 10:00 a.m. ET...

VYNE : 2.50 (+4.60%)
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated...

VYNE : 2.50 (+4.60%)
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update

FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and...

VYNE : 2.50 (+4.60%)

Business Summary

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

See More

Key Turning Points

3rd Resistance Point 2.77
2nd Resistance Point 2.66
1st Resistance Point 2.58
Last Price 2.50
1st Support Level 2.39
2nd Support Level 2.28
3rd Support Level 2.20

See More

52-Week High 3.43
Fibonacci 61.8% 2.72
Fibonacci 50% 2.50
Last Price 2.50
Fibonacci 38.2% 2.28
52-Week Low 1.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar